Biomarker ID | 573 |
PMID | 21098088 |
Year | 2011 |
Biomarker | miR-223; miR-24; |
Biomarker Basis | Expression Based |
Biomolecule | miRNA |
Source | Serum |
Subjects | Humans |
Regulation | Downregulated in PCa |
Odds Ratio/Hazard Ratio/Relative Risk | NA |
Effect on Pathways | Pathways Include(miR-223):-synapse; Adipogenesis; immune system development; positive regulation of transcription by RNA polymerase II; hemopoiesis Pathways Imclude (miR-24):- nucleoplasm; intracellular membrane-bounded organelle; intracellular organelle; synapse; organelle membrane |
Experiment | Healthy Vs High Risk (CAPRA>5) |
Type of Biomarker | Diagnostic |
Cohort | A total of 48 patients, 12 heathy and 36 with prostate cancer (CAPRA score: CAPRA1 (n=12), CAPRA4 (n=12), CAPRA 5-7 (n=12)) were chosen for the study. |
Senstivity | NA |
Specificity | NA |
AUC | NA |
Accuracy | NA |
Level Of Significance | miR-223 p= 0.002; miR-24 p=0.02 |
Method Used | qRT-PCR |
Clinical | No |
Remarks | CAPRA score defined as: Cancer of the prostate risk assesment was based on the patients’ age, PSA level, clinical tumor stage, Gleason score, and percentage of biopsy cores positive for cancer at diagnosis, |
Clinical Trial Number | NA |
Degree Of Validity | Not validated on independent patient dataset |
Technical Name | miR-223, miR-24 |